SANTA ANA, Calif., Sept. 21, 2017 /PRNewswire/ -- The company's historical first FDA-approved portable and tubeless DVT prevention device is now available to medical practitioners and patients throughout the United States.
"We at ManaMed are thrilled that our innovative PlasmaFlow DVT prevention device is available to help mitigate the risk to 600,000-plus new cases of DVT every year in the USA," says Trevor Theriot, Co-Founder and CEO of Manamed. Theriot adds: "Blood Clots are a silent killer in the medical industry and we decided to up the fight against DVT related deaths." PlasmaFlow is the first FDA-approved portable and tubeless sequential device with multiple pressure functions. Designed for optimal results and patient comfort, PlasmaFlow features innovative step-up-technology, user-friendly one-button operation, soft cuffs made of high-grade medical material, up to 10hours of battery life, rechargeable, two LCD screens with timer and verification of pressure, and graduated and asymmetric compression for maximum benefit.
A thriving demand for ease in treatment is provided by PlasmaFlow. Tubeless and portable, PlasmaFlow is intended for use at home or at the hospital to help prevent the onset of DVT in patients by stimulating blood flow in the extremities. PlasmaFlow can be used to prevent DVT, enhance blood circulation, reduce post-operative pain and swelling, reduce wound healing time, aid in the treatment of stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiently and reduction of edema in the lower limbs. The device can also be used as an aid in the prophylaxis for DVT by people stationary for long periods of time.
The risk of getting a blood clot is highest during and 14 days after surgery, and goes down with time. PlasmaFlow should be used anytime during post-surgery recovery when a patient is sitting, resting or laying down. PlasmaFlow, prescribed by a physician, allows a multimodal approach for venous thromboembolism (VTE) for high-risk orthopedic surgery patients. Current Board guidelines indicate that aspirin is not appropriate as the only option for the prevention of DVT. Unlike prescriptive drugs, PlasmaFlow helps mitigate the risk of bleeding and does not require weekly blood monitoring.
Theriot adds: "With our FDA approval we feel PlasmaFlow is a great leap for mankind toward DVT prevention and we will remain on the cutting edge toward pioneering a wide range of innovative physical therapy devices all geared toward making daily life a better experience for all."
About ManaMed www.manamed.net
With over 40 years of combined medical experience, ManaMed offers innovative solutions, superior customer services and a well-educated distribution network. Visit www.manamed.net
Many cases of DVT and Pulmonary Embolisms fall under the Hospital-Acquired Conditions under the Deficit Reduction Act of 2005 and may results in penalties and payment reductions. PlasmaFlow is covered by most insurances as they recognize the significant cost savings when a patient does not have to be readmitted to a hospital. PlasmaFlow is an innovative solution for a hospital's bundles payment system, the increase of medical tourism, and decreased discharges times.
SOURCE ManaMed Inc.